Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that severe androgenic alopecia in hospitalized men was associated with a higher likelihood of testing positive for COVID-19.

In this study, 76% of hospitalized COVID-19 patients experienced post-COVID-19 syndrome with symptoms like difficulty concentrating and fatigue lasting around 150 days, significantly impacting their quality of life through increased pain, discomfort, and anxiety.

This study found that patients over 45, those with obesity, and those experiencing 15 or more COVID-19 symptoms had a higher likelihood of developing severe long COVID-19.

This study reported that Lung-Ultrasound effectively monitors lung recovery in COVID-19 ARDS survivors, and identified a link between high EPAP-CPAP pressure and cardiopulmonary impairment.

This study observed that 6.5% of COVID-19 patients requiring inpatient or emergency care developed hair loss, compared to 4.7% of those treated as outpatients, suggesting COVID-19 severity may influence hair loss risk.

This letter discusses how severe baldness in men is associated with higher risk of severe COVID-19, and highlights research suggesting antiandrogen medications may improve outcomes.

In this case report, a 33-year-old woman with severe post-COVID alopecia areata experienced hair regrowth after two months of treatment with topical minoxidil, tacrolimus, and scalp PRP with micro-needling, though some bald patches reoccurred.

This research discusses androgenic alopecia's potential role in severe COVID-19 symptomatology and suggests further exploration of the scalp's role in virus transmission.

This study found that patients who were hospitalized for COVID-19 were more likely to develop telogen effluvium, a type of hair loss, compared to those treated as outpatients, suggesting a link between COVID-19 severity and this condition.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

This study found no statistically significant differences in extracellular water and cardiac measurements between COVID-19 patients in intensive care and those on the ward, though the NICaS device might aid fluid management.

This review discusses vaccine safety concerns for individuals with autoimmune and inflammatory conditions, noting vaccine hesitancy due to observed exacerbations post-vaccination and a lack of comprehensive trial data.

This study found no significant difference in the persistence of new symptoms or quality of life improvements with 200,000 IU of vitamin D3 compared to placebo in patients post-COVID-19 hospitalization.

This article discusses potential links between male balding, specifically androgenic alopecia, and severe COVID-19, suggesting that balding may serve as a biomarker for identifying higher-risk patients, but it reports no new experimental findings.

This case report describes a 6-year-old girl who developed MIS-C following COVID-19 vaccination, raising questions about the vaccine's potential role in its pathogenesis for children aged 5 to 11.

This case study reports that zinc supplementation significantly improved the symptoms of Acrodermatitis Enteropathica in a 12-year-old boy, emphasizing the importance of early diagnosis and treatment compliance.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

This case study potentially links the use of anabolic steroids to increased severity of COVID-19 in a healthy 28-year-old man, with marked symptom improvement following treatment with proxalutamide.

Stem cell therapies, especially adipose-derived ones, show promise for treating severe COVID-19 and related conditions.

This study suggests that the Gabrin sign and hypertension in male patients are associated with a worse prognosis for COVID-19.

In this study, researchers observed that patients with COVID-19 can develop a variety of skin lesions, with maculopapular rash, telogen effluvium, and urticaria showing significant associations with both the timing of symptom onset and the severity of the disease.

This review examines biological reasons for sex-based differences in COVID-19 outcomes, noting that females exhibit stronger immune responses, potentially explaining lower severity and mortality compared to males.

This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

The researchers reported a case of Beau's lines in a 65-year-old man, potentially linked to past severe COVID-19 infections, suggesting that identifying these nail changes might signal prior infection and increased risk of reinfection.

In this review, researchers reported that post-COVID-19 syndrome may lead to significant sequelae like hair loss, potentially due to acute telogen effluvium, affecting around 20% of patients and impacting their quality of life, though specific studies on this relationship are lacking.

This study found a high prevalence of telogen effluvium among patients hospitalized for severe COVID-19, with most experiencing early onset and eventual complete hair regrowth.

In this study, 19.6% of COVID-19 vaccine recipients reported post-vaccination mucocutaneous effects, mostly mild and self-limiting; the reactions were similarly frequent for Covishield and Covaxin.

This study found that patients with COVID-19 infection lasting longer than two weeks experienced more severe post-infection hair loss, with women and older individuals particularly affected.

This report describes a severe COVID-19 case in a patient with SLE and nephritis, where hydroxychloroquine improved outcomes after regular use.

This case report identifies severe acute hair loss and headache as potential symptoms or complications of COVID-19 in the context of a 51-year-old woman with hypothyroidism.